Drug intelligence / Profile preview

SPC-54

Development stage: Preclinical
Lead developer: Scripps Research
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

SPC-54 is a rat monoclonal antibody that specifically targets and inhibits mouse activated protein C (APC). It binds to the active site of APC, thereby neutralizing its enzymatic activities, which include both its anticoagulant functions (cleavage of Factors Va and VIIIa) and its cytoprotective signaling via Protease-Activated Receptor-1 (PAR-1). SPC-54 is primarily utilized as a research tool in preclinical mouse models to investigate the physiological and pathological roles of the protein C pathway in conditions such as sickle cell disease (SCD), sepsis, and thrombo-inflammation. The antibody was developed and characterized by researchers at The Scripps Research Institute.

Other names: anti-mouse protein C mAbanti-APC SPC54

Targets

PROC (Protein C)

Beyond the preview

Go deeper on SPC-54.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPC-54.

Explore the full profile